S Shahzad Mustafa1,2, David Ostrov3, Daniel Yerly4. 1. Allergy and Clinical Immunology, Rochester Regional Health System, Rochester, NY, USA. shahzad.mustafa@rochesterregional.org. 2. University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. shahzad.mustafa@rochesterregional.org. 3. Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA. 4. Department of Rheumatology, Immunology and Allergology, University Hospital and University of Bern, Bern, Switzerland.
Abstract
PURPOSE OF STUDY: Immune-mediated adverse drug reactions occur commonly in clinical practice and include mild, self-limited cutaneous eruptions, IgE-mediated hypersensitivity, and severe cutaneous adverse drug reactions (SCAR). SCARs represent an uncommon but potentially life-threatening form of delayed T cell-mediated reaction. The spectrum of illness ranges from acute generalized exanthematous pustulosis (AGEP) to drug reaction with eosinophilia with systemic symptoms (DRESS), to the most severe form of illness, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). RECENT FINDINGS: There is emerging literature on the efficacy of cyclosporine in decreasing mortality in SJS/TEN. The purpose of our review is to discuss the typical presentations of these conditions, with a special focus on identifying the culprit medication. We review risk factors for developing SCAR, including HLA alleles strongly associated with drug hypersensitivity. We conclude by discussing current strategies for the management of these conditions.
PURPOSE OF STUDY: Immune-mediated adverse drug reactions occur commonly in clinical practice and include mild, self-limited cutaneous eruptions, IgE-mediated hypersensitivity, and severe cutaneous adverse drug reactions (SCAR). SCARs represent an uncommon but potentially life-threatening form of delayed T cell-mediated reaction. The spectrum of illness ranges from acute generalized exanthematous pustulosis (AGEP) to drug reaction with eosinophilia with systemic symptoms (DRESS), to the most severe form of illness, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). RECENT FINDINGS: There is emerging literature on the efficacy of cyclosporine in decreasing mortality in SJS/TEN. The purpose of our review is to discuss the typical presentations of these conditions, with a special focus on identifying the culprit medication. We review risk factors for developing SCAR, including HLA alleles strongly associated with drug hypersensitivity. We conclude by discussing current strategies for the management of these conditions.
Entities:
Keywords:
Acute generalized exanthematous pustulosis (AGEP); Drug reaction with eosinophilia and systemic symptoms (DRESS); HLA-associated drug hypersensitivity; Severe cutaneous adverse drug reaction (SCAR); Stevens-Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)
Authors: Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: P Wolkenstein; J Latarjet; J C Roujeau; C Duguet; S Boudeau; L Vaillant; M Maignan; M H Schuhmacher; B Milpied; A Pilorget; H Bocquet; C Brun-Buisson; J Revuz Journal: Lancet Date: 1998-11-14 Impact factor: 79.321
Authors: Lukas Jörg-Walther; Benno Schnyder; Arthur Helbling; Karin Helsing; Alexandra Schüller; Annette Wochner; Werner Pichler Journal: Clin Case Rep Date: 2015-08-26
Authors: Hyun Jung Jin; Dong Yoon Kang; Young Hee Nam; Young Min Ye; Young Il Koh; Gyu Young Hur; Sae Hoon Kim; Min Suk Yang; Sujeong Kim; Yi Yeong Jeong; Min Hye Kim; Jeong Hee Choi; Hye Ryun Kang; Eun Jung Jo; Hye Kyung Park Journal: Allergy Asthma Immunol Res Date: 2021-03 Impact factor: 5.764
Authors: Amber N Edinoff; Long H Nguyen; Mary Jo Fitz-Gerald; Erin Crane; Kyle Lewis; Samantha St Pierre; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Sonja A Gennuso; Giustino Varrassi; Omar Viswanath; Ivan Urits Journal: Psychopharmacol Bull Date: 2021-03-16
Authors: E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck Journal: J Eur Acad Dermatol Venereol Date: 2020-05-15 Impact factor: 6.166